Sana Biotechnology (NASDAQ:SANA) Given New $11.00 Price Target at HC Wainwright

Sana Biotechnology (NASDAQ:SANA) had its target price upped by investment analysts at HC Wainwright from $8.00 to $11.00 in a research note issued to investors on Wednesday,Benzinga reports. The brokerage presently has a “buy” rating on the stock.

Several other brokerages have also recently weighed in on SANA. JMP Securities cut Sana Biotechnology from an “outperform” rating to a “market perform” rating in a research note on Tuesday, November 5th. TD Cowen raised shares of Sana Biotechnology from a “hold” rating to a “buy” rating in a research report on Wednesday. One equities research analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $14.25.

Sana Biotechnology Price Performance

NASDAQ:SANA opened at $1.65 on Wednesday. Sana Biotechnology has a one year low of $1.52 and a one year high of $12.00. The company has a market cap of $368.39 million, a PE ratio of -1.18 and a beta of 1.45. The firm has a 50-day moving average of $2.38 and a 200-day moving average of $4.07.

Sana Biotechnology (NASDAQ:SANA) last issued its quarterly earnings data on Friday, November 8th. The company reported ($0.25) EPS for the quarter, topping analysts’ consensus estimates of ($0.26) by $0.01. On average, equities research analysts expect that Sana Biotechnology will post -1.16 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of SANA. FMR LLC raised its stake in shares of Sana Biotechnology by 16.3% during the 3rd quarter. FMR LLC now owns 31,609,175 shares of the company’s stock worth $131,494,000 after purchasing an additional 4,438,949 shares during the period. Geode Capital Management LLC raised its position in Sana Biotechnology by 9.6% in the third quarter. Geode Capital Management LLC now owns 3,166,480 shares of the company’s stock worth $13,175,000 after acquiring an additional 276,055 shares during the period. State Street Corp boosted its stake in Sana Biotechnology by 4.2% in the third quarter. State Street Corp now owns 6,627,320 shares of the company’s stock valued at $27,570,000 after acquiring an additional 269,274 shares during the last quarter. Integral Health Asset Management LLC grew its position in shares of Sana Biotechnology by 22.4% during the 2nd quarter. Integral Health Asset Management LLC now owns 1,200,000 shares of the company’s stock valued at $6,552,000 after acquiring an additional 220,000 shares during the period. Finally, Barclays PLC increased its stake in shares of Sana Biotechnology by 126.6% during the 3rd quarter. Barclays PLC now owns 318,910 shares of the company’s stock worth $1,325,000 after purchasing an additional 178,179 shares during the last quarter. Institutional investors own 88.23% of the company’s stock.

About Sana Biotechnology

Sana Biotechnology, Inc, a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others.